November 28, 2025
Mr. Gottheimer (for himself and Mrs. Kiggans of Virginia) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
To amend title XVIII of the Social Security Act to require coverage of lung cancer biomarker testing under the Medicare program.
Section 1. Short title
This Act may be cited as the Lung Cancer Medicare Access to Precise Testing Act
.
Sec. 2. Requiring coverage of lung cancer biomarker testing under Medicare
(a) Coverage
Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended—
(1)
in subsection (s)(2)—
(A)
in subparagraph (JJ), by adding and
at the end; and
(B)
by adding at the end the following new subparagraph:
(KK)
lung cancer biomarker testing (as defined in subsection (nnn));; and
(2)
by adding at the end the following new subsection:
(nnn) Lung cancer biomarker testing
The term lung cancer biomarker testing means a test furnished on or after January 1, 2027, to an individual diagnosed with lung cancer for the identification of 1 or more specific biomarkers (such as genes, proteins, or other molecules) based on the analysis of such individual’s tissue, blood, or bodily fluids.
(b) Payment
Section 1833(a)(1) of the Social Security Act (42 U.S.C. 1395y(a)(1)) is amended—
(1)
by striking and (HH)
and inserting (HH)
; and
(2)
by inserting , and (II) with respect to lung cancer biomarker testing (as defined in section 1861(nnn)), the amount paid shall be 100 percent of the reasonable charges for such testing
before the semicolon at the end.